A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Ribociclib (Primary) ; Fulvestrant; Goserelin; Letrozole; Tamoxifen
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 28 Jun 2017 Planned End Date changed from 12 Apr 2019 to 5 Oct 2018.
- 28 Jun 2017 Planned primary completion date changed from 12 Apr 2019 to 6 Sep 2018.
- 17 Apr 2017 Planned End Date changed from 14 Jun 2019 to 12 Apr 2019.